Отдаленные результаты и прогнозирование выживаемости после резекции печени у больных с метастазами колоректального рака
Диссертация
На основании определения прогностических факторов, достоверно влияющих на выживаемость больных после резекции печени при метастазах КРР, разработана шкала прогноза выживаемости больных с метастазами КРР в печень, базирующаяся на клинических и лабораторных факторах. В зависимости от числа неблагоприятных прогностических факторов все пациенты могут быть разделены на группы с достоверно… Читать ещё >
Список литературы
- Вишневский В.А., Кубышкин В. А., Чжао A.B., Икрамов Р. З. Операции напечени. Руководство для хирургов. М.: «МИКЛОШ», 2003.-155с.
- Гранов Д.А., Таразов П. Г., Гранов Д. А. и др. Современные тенденции в комбинированном хирургическом лечении первичного и метастатического рака печени. Анналы хир гепатол 2002- 2: 9—17.
- Гальперин Э.И. Актуальные вопросы резекции печени. Хирургия 1980- 1:49−57.
- Давыдов М.И., Аксель Е. М. Статистика злокачественных новообразований в России и странах СНГ в 2008 г. Вестн. Рос. онкол. центра им. Н. Н. Блохина РАМН. 2010- 21, 3 (прил. 1).
- Ефанов М.Г. Сегментарные резекции при очаговых образованиях печени. Дисс. д-ра мед. наук: 14.01.17 Хирургия / Институт хирургии им. A.B.Вишневского. — М., 2010. — 333с.
- Журавлев В.А. Анатомическая резекция печени операция выбора. // Анналы хирургической гепатологии. — 2003. — Том 8. — № 2. — С. 43 — 47.
- Журавлев В.А. Большие и предельно большие резекции печени. Саратов 1986.
- Иванов A.A. Повторные операции при злокачественных опухолях печени. Автореферат дисс.. канд. медицинских наук.- М., 2009.- 26с.
- Назаренко H.A. Обширные резекции печени. Автореферат на соиск. доктора мед наук. Москва 2005. С. 22−26.
- Патютко Ю.И. Хирургическое лечение злокачественных опухолей печени. М.: Практическая медицина. 2005. С.
- Патютко Ю.И., Пылев А. Л., Сагайдак И. В. и др. Хирургическое икомбинированное лечение больных с поражением печени и регионарныхлимфатических узлов метастазами колоректального рака. Хирургия.
- Журнал им. Н.И. Пирогова, 2010−7:49−54.115
- Патютко Ю.И., Сайгадак И. В. Показания и противопоказания к резекциям печени по поводу метастазов колоректального рака. Ценность факторов прогноза и их классификация. Анналы хир гепатол 2003- 1: 10—18.
- Патютко Ю.И., Чучуев Е. С., Подлужный Д. В., Поляков А. Н., Агафонова М. Г. Хирургическая тактика в лечении больных колоректальным раком с синхронными метастазами в печень. Онкологическая колопроктология. 2011. № 2. 13−19.
- Полищук JI.O., Козмин Л. Д., Скипенко О. Г. Непосредственные результаты резекции печени после неоадъювантной химиотерапии колоректального рака. Хирургия. Журнал им. Н. И. Пирогова, 2010- 1:3040.
- Поляков А.Н. Комбинированное лечение метастазов колоректального рака в печени. Автореферат дисс.. канд. медицинских наук.- М., 2009.26 с.
- Сагайдак И.В. Хирургическое и комбинированное лечение больных с метастазами рака толстой кишки в печень. Автореферат дисс. докт. медицинских наук. М., 2003. — 40с.
- Хирургия печени и желчных протоков/ Под ред. Шалимова А. А. Киев, 1975. С. 75.
- Хирургия печени и желчных протоков. Под ред. Б. И. Альперовича. Томск 1997.
- Шапкин B.C. Резекция печени. М.: Медицина. 1967. С. 25−26.
- Adam R, Avisar Е, Ariche A, Giachetti S, Azoulay D, Castaing D, et al. Five-year survival following hepatic resection after neoadjuvant therapy for non-resectable colorectal liver. metastases. Ann Surg Oncol. 2001−8:347−353.
- Adam R., Bismuth H., Castaing D., et al. Repeat hepatectomy for colorectal liver metastases. // Ann Surg. 1997. — № 225. — P. 51 — 60.
- Adam R, de Haas RJ, Wicherts DA, Aloia ТА, Delvart V, Azoulay D,
- Bismuth H, Castaing D. Is hepatic resection justified after chemotherapy in116patients with colorectal liver metastases and lymph node involvement? J Clin Oncol. 2008−26:3672−3680.
- Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg. 2000−232:777−785.
- Adam R., Pascal G., Azoulay D., et al. Liver Resection for Colorectal Metastases. The Third Hepatectomy. // Annals of Surgery. 2003. — Vol. 238. -№ 6. — P. 871 -883.
- Adam R, Miller R, Pitombo M, Wicherts DA, de Haas RJ, Bitsakou G, Aloia T. Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases. Surg Oncol Clin N Am. 2007−16:525−536.
- Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: Myth or reality? J Clin Oncol. 2008- 26:1635−1641.
- Aloia T., Sebagh M., Plasse M. et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006- 24:4983—4990.
- Are C, Gonen M, Zazzali K, Dematteo RP, Jarnagin WR, Fong Y, et al. The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg. 2007−246:295−300.
- Bismuth H, Adam R. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin Oncol. 1998−25:40−46.
- Blazer DG, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008−26:5344−5351.
- Bockhorn M, Frilling A, Fruhauf NR, Neuhaus J, Molmenti E, Trarbach T, Malago M, Lang H, Broelsch CE. Survival of patients with synchronous and metachronous colorectal liver metastases is there a difference. J Gastrointest Surg. 2008−12:1399−1405.
- Bodingbauer M, Tamandl D, Schmid K, Plank C, Schima W, Gruenberger T. Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases. Br J Surg. 2007−94:1133— 1138.
- Bokemeyer C, Bondarenko I, Hartmann J, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study by Bokemeyer et al Annals of Oncology 22:1535−1546,2011.
- Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin 0ncol.2009−27:663−671. PubMed.
- Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg. 2000−231:743−751.
- Bozzetti F., Doci R., Bignami P., et al., Patterns of failure following surgical resection of colorectal cancer liver metastases. Rationale for a multimodal approach. // Ann Surg. 1987. — № 205. — P. 264 — 270.
- Cao CQ, Yan TD, Liauw W, Morris DL. Comparison of optimally resected hepatectomy and peritonectomy patients with colorectal cancer metastasis. J Surg Oncol. 2009 Dec l-100(7):529−33.
- Carpizo DR, D’Angelica M. Liver Resection for Metastatic Colorectal Cancer in the Presence of Extrahepatic Disease. Ann Surg Oncol. 2009- 16:24 112 421.
- Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006 0ct-13(10): 1261−8. Epub 2006 Sep 1.
- De Raffele E., Mirarchi M., Vaccari S., et al. Intra and postoperative clinical outcome following repeat hepatectomy for primary or metastatic liver cancer.// HPB. 2009. — vol. 11.- suppl. 2. — P. 98.
- Dopazo C., Bilbao I., Sapisochin G., et al. Are repeat liver resections a safe and effective treatment for recurrent colorectal liver metastases? // HPB., -2009. vol. 11.- suppl. 2. — P. 102.
- Dries Vandeweyer, Eu Ling Neo, John WC Chen, Guy J Maddern, Thomas G Wilson, Robert TA Padbury. Influence of resection margin on survival in hepatic resections for colorectal liver metastases HPB (Oxford) 2009 September- 11(6): 499−504.
- Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002−3:991−998.
- Eid E.A., Sheta S.A., Mansour E., et al. Low central venous pressure anesthesia in major hepatic resection.// Middle East J Anesthesiol. 2005. -Vol. 18.-№ 2.-P. 367−377.
- Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hagerstrand I, Ranstam J, Bengmark S. Determinants of survival in liver resection for colorectal secondaries. Br J Surg. 1986 Sep-73(9):727−31.
- Elias D, Ouellet JF, Bellon N, Pignon JP, Pocard M, Lasser P. Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg. 2003−90:567−574.
- Elias D, Ouellet JF, Bellon N, Pignon JP, Pocard M, Lasser P. Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg. 2003−90:567−574.
- Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005−200:845−853.
- Fernandez-Trigo V., Shamsa F., Sugarbaker P.H. Repeat liver resections from colorectal metastasis. Repeat Hepatic Metastases Registry. //Surgery. 1995. -№ 117-P. 296−304.
- Folprecht G, Gruenberger T, et al. Tumor response and secondary respectability of colorectal liver metastatses following neoadjuvant chemotherapy with cetuximab: the CELIM randomized phase 2 trial. Lancet Oncol 2010- 11:38−47.
- Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999−230:309−318.
- Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, et al. Guidelines for resection of colorectal cancer liver metastases. Gut. 2006−55(Suppl. 3):l-8.
- Garcea G, Polemonivi N, O’Leary E, Lloyd TD, Dennison AR, Berry DP. Two-stage liver resection and chemotherapy for bilobar colorectal liver metastases. Eur J Surg Oncol.2004−30:759−764.
- Gertsch P. A historical perspective on colorectal liver metastases and peritoneal carcinomatosis: similar results, different treatments. Surg Oncol Clin N Am. 2003−12:531−41.
- Goede V., Coutelle O., Neuneier J. et al. Identification of serum angiopoietin2as a biomarker for clinical outcome of colorectal cancer patients treated withbevacizumab containing therapy // Brit. J. Cancer. 2010, Oct. 26.
- Vol. 103(9). P.14 071 414. -Epub. — 2010, Oct. 5.122
- Gomez D, Morris-Stiff G, Wyatt J, Toogood GJ, Lodge JP, Prasad KR. Surgical technique and systemic inflammation influences long-term disease-free survival following hepatic resection for colorectal metastasis. J Surg Oncol. 2008 Oct l-98(5):371−6.
- Goldberg RM, Meropol NJ, Tabernero J. Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer. Gastrointest Cancer Res. 2009−3(suppl 2):S23-S27.
- Govindarajan A, Paty PB. Predictive markers of colorectal cancer liver metastases. Future Oncol. 2011 Feb-7(2):299−307.
- Gruenenberger B, Tamandi D, Schueller J, et al. Bevacizumab, capecitabine and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin 0ncol.2008−26:1830−1835.
- Gruenenberger B, Scheithauer W, Punzengruber R, et al. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer metastases. BMC Cancer. 2008−8:120.
- Grunberg T. Changing paradigms in systemic mCRC treatment where thesurgeon and medical oncologist meet. Представлено на сателлитном симпозиуме XV Россиийского онкологического конгресса. 15−17 ноября Москва. 2011.
- Gulec SA, Fong Y. Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases. Arch Surg. 2007−142:675−682. 79. Heriot AG, Karanjia ND. A review of techniques for liver resection. Ann R Coll Surg Engl.2002−84:371−380.
- Imamura H, Seyama Y, Kokudo N, Maema A, Sugawara Y, Sano K, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg. 2003−138:1198−1206.
- Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 1999−189:291−299.
- Jaeck D, Bachellier P, Nakano H, Oussoultzoglou E, Weber JC, Wolf P, Greget M. One or two-stage hepatectomy combined with portal vein embolization for initially nonresectable colorectal liver metastases. Am J Surg. 2003−185:221−229.
- Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC, Bachellier P. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar
- Kaido T, Uemoto S. Quality assessment of randomized controlled trials involving liver surgery.Hepatogastroenterology. 2008−55:1678−80.
- Kanemitsu Y, Kato T, Hirai T, Yasui K. Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg. 2004−91:112−120.
- Konopke R, Kersting S, Distler M, Dietrich J, Gastmeier J, Heller A, et al. Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int. 2009−29:89−102.
- Kornprat P, Jarnagin WR, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, D’Angelica M. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol. 2007−14:1151−1160.
- Lee WS, Kim MJ, Yun SH, Chun HK, Lee WY, Kim SJ, et al. Risk factor stratification after simultaneous liver and colorectal resection for synchronous colorectal metastasis. Langenbecks Arch Surg. 2008−393:13−19.
- Madoff DC, Abdalla EK, Vauthey JN. Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care. J Vase Interv Radiol. 2005−16:779−790.
- Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunven P, Yamazaki S, Hasegawa H, Ozaki H. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery. 1990−107:521−527.
- Malik HZ, Prasad KR, Halazun KJ, Aldoori A, Al-Mukhtar A, Gomez D, et al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg. 2007−246:806−814.
- Malik HZ, Farid S, Al-Mukthar A, Anthoney A, Toogood GJ, Lodge JP, et al. A critical appraisal of the role of neoadjuvant chemotherapy for colorectal liver metastases: a case-controlled study. Ann Surg Oncol. 2007- 14:35 193 526.
- Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006−244:254−259.
- Martin RC, 2nd, Augenstein V, Reuter NP, Scoggins CR, McMasters KM. Simultaneous versus staged resection for synchronous colorectal cancer liver metastases. J Am Coll Surg. 2009−208:842−850.
- McLoughlin JM, Jensen EH, Malafa M. Resection of colorectal liver metastases: current perspectives. Cancer Control. 2006 Jan-13(l):32−41.
- Memon MA, Beckingham IJ. Surgical resection of colorectal liver metastases. Colorectal Dis. 2001 Nov-3(6):361−73.
- Mehta NN, Ravikumar R, Coldham CA, Buckels JA, Hubscher SG, Bramhall SR, et al. Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur J Surg Oncol.2008−34:782−786.
- Mentha G, Roth AD, Terraz S, Giostra E, Gervaz P, Andres A, Morel P, Rubbia-Brandt L, Majno PE. 'Liver first' approach in the treatment of colorectal cancer with synchronous liver metastases. Dig Surg. 2008−25:430−435.
- Miller G, Biernacki P, Kemeny NE, Gonen M, Downey R, Jarnagin WR, D’Angelica M, Fong Y, Blumgart LH, DeMatteo RP. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg. 2007−205:231−238.
- Mineo TC, Ambrogi V, Tonini G, Bollero P, Roselli M, Mineo D, et al. Longterm results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma. J Am Coll Surg. 2003−197:386−391.
- Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, Yamamoto J, Imamura H. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg. 2000−231:487−499.
- Mitry E, Fields ALA, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: A pooled analysis of two randomized trials. J Clin 0ncol.2008−26:4906−4911.
- Mohamed F., Cecil T. et al. A new standard of care for the management of peritoneal surface malignancy. Curr Oncol. 2011 April- 18(2): e84—e96
- Muratore A, Polastri R, Bouzari H, Vergara V, Ferrero A, Capussotti L. Repeat hepatectomy for colorectal liver metastases: a worthwhile operation? J Surg Oncol. 2001−76:127−132.
- Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, Nunez R, Habbu A, Liu D, Ross W, et al. Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. J Vase Interv Radiol. 2007−18:553−561.
- Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998−58:3491−3494.
- Ng WW, Cheung YS, Wong J, Lee KF, Lai PB. A preliminary analysis of combined liver resection with new chemotherapy for synchronous and metachronous colorectal liver metastasis. Asian J Surg. 2009−32:189−197.
- Nishio H, Hamady ZZ, Malik HZ, Fenwick S, Rajendra Prasad K, Toogood GJ, et al. Outcome following repeat liver resection for colorectal liver metastases. Eur J Surg Oncol. 2007−33:729−734.
- Nordlinger B., Vaillant J.C., Guiguet M., et al. Survival benefit of repeat liver resections for recurrent liver metastases from colorectal metastases: 143 cases. Association Francaise de Chirurgie. // J Clin Oncol. 1994. — № 12. -P.: 1491−1496.
- Ohtani H. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun. 2007−7:4.
- Parks R, Gonen M, Kemeny N, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg. 2007−204:753−761. PubMed.
- Pawlik TM, Abdalla EK, Ellis LM, Vauthey JN, Curley SA. Debunking dogma: surgery for four or more colorectal liver metastases is justified. J Gastrointest Surg. 2006−10:240−248.
- Pawlik TM, Choti MA. Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases. Curr Oncol Rep. 2007 May-9(3): 193−201.
- Petrowsky H., Gonen M., Jarnagin W., et al. Second Liver Resections Are Safe and Effective Treatment for Recurrent Hepatic Metastases from Colorectal Cancer. A Bi-institutional Analysis // Annals of Surgery. 2002. -Vol.235. — No. 6.-P. 863−871.
- Puthillath A, Dunn KB, Rajput A, Smith J, Yang G, Wilding GE, Tan W, Gupta B, Fakih MG. Safety and efficacy of first-line chemotherapy in unresected metastatic colorectal cancer. Clin Colorectal Cancer. 2007−6:710−715. doi: 10.3816/CCC.2007.n.040.
- Que F.G., Nagorney D.M. Resection of «recurrent» colorectal metastases of the liver. // Br J Surg. 1994. — № 81. — P. 255−258.
- Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG. Evaluation of longterm survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008−247:125−135.
- Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990 Nov-77(ll): 1241−6.
- Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995−19:59−71.
- Schindl M, Wigmore SJ, Currie EJ, Laengle F, Garden OJ. Prognostic scoring in colorectal cancer liver metastases: development and validation. Arch Surg. 2005−140:183−189.
- Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol. 1999−6:651−657.
- Seblini M., Boleslawski E., Truant S., et al. Rehepatectomy for colorectal liver metastases: are morbidity and survival influenced by the extent of the first resection? // HPB., 2009. — vol. 11.- suppl. 2. — P. 94.
- Shen P, Stewart JH, Levine EA. Metastases of colorectal cancer to the liver and peritoneum: comparison of surgical paradigms. Expert Rev Anticancer Ther. 2008 Nov-8(ll): 1797−808.
- Sherif Raafat Zikry Abdel-Misih, Carl R Schmidt, and Paul Mark Bloomston. Update and review of the multidisciplinary management of stage IV colorectal cancer with liver metastases. World J Surg Oncol. 2009- 7: 72.
- Shimada H, Tanaka K, Masui H, Nagano Y, Matsuo K, Kijima M, Ichikawa Y, Ike H, Ooki S, Togo S. Results of surgical treatment for multiple (> or = 5 nodules) bi-lobar hepatic metastases from colorectal cancer. Langenbecks Arch Surg. 2004−389:114−121.
- Siena S, Cassidy J, Tabarnero J. et al. Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as first-line treatment for metastatic colorectal cancer: the PRIME trial. Presented at:
- Gastrointestinal Cancer Symposium- January 22−24- Orlando-Florida 2010.130
- Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001−2:293−299.
- South CD, Meyer MM, Meis G, Kim EY, Thomas FB, Rikabi AA, Kahbiri H, Bloomston M. Yttrium-90 microsphere induced gastrointestinal tract ulceration. World J Surg Oncol. 2008−6:93.
- Suzuki S, Sakaguchi T, Yokoi Y, Kurachi K, Okamoto K, Okumura T, et al. Impact of repeat hepatectomy on recurrent colorectal liver metastases. Surgery. 2001−129:421−428.
- Starling N, Cunningham D, Velasquez F, et al. A phase I study of sunitinib combination with FOLFIRI chemotherapy in treatment naive metastatic colorectal cancer. 2007 ASCO Gastrointestinal Cancers Symposium- Orlando, FL. Jan 19−21, 2007. (abstr 319)
- Takahashi S, Nagai K, Saito N, Konishi M, Nakagohri T, Gotohda N, et al. Multiple resections for hepatic and pulmonary metastases of colorectal carcinoma. Jpn J Clin Oncol. 2007−37:186−192.
- Tanaka K., Shimada H., Matsuo K. et al. Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. Surgery 2004- 136(3): 650−9.
- Tie J., Lipton L., Desai J. et al. KRAS Mutation is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer // Clin. Cancer. Res. 2011, Jan. 14. — Epub Ahead of Print.
- Togo S, Nagano Y, Masui H, Tanaka K, Miura Y, Morioka D, Endo I, Wekido H, Ike H, Shimada H. Two-stage hepatectomy for multiple bilobular liver metastases from colorectal cancer. Hepatogastroenterology. 2005 -52:913−919.
- Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D1 Angelica M. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007−25:4575−4580.
- Tsai MS, Su YH, Ho MC, Liang JT, Chen TP, Lai HS, Lee PH. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol. 2007−14:786−794.
- Ueno H, Mochizuki H, Hatsuse K, Hase K, Yamamoto T. Indicators for treatment strategies of colorectal liver metastases. Ann Surg. 2000−231:59−66.
- Vallbohmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol. 2005−23(15):3536−3544.
- Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009−360:1408−1417.
- Wang X, Hershman DL, Abrams JA, Feingold D, Grann VR, Jacobson JS, Neugut AI. Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br J Cancer. 2007−97:1606−1612.
- Wicherts DA, Miller R, de Haas RJ, Bitsakou G, Vibert E, Veilhan LA, et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg. 2008−248:994−1005.
- Yamada H, Katoh H, Kondo S, Okushiba S, Morikawa T. Repeat hepatectomy for recurrent hepatic metastases from colorectal cancer. Hepatogastroenterology. 2001 -48:828−830.
- Yan T.Y., Sim J., Black D., et al., Systematic review on safety and efficacy of repeat hepatectomy for recurrent liver metastases from colorectal carcinoma. // Annals of Surgical Oncology. 2007. — 14. — P. 2069 — 2077.
- Zakaria S, Donohue JH, Que FG, Farnell MB, Schleck CD, Ilstrup DM, et al. Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg. 2007−246:183−191.
- Zhang W, Gordon M, Press OA, et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with cetuximab. Pharmacogenet Genomics. 2006- 16(7):475−483.
- Zlobec I, Steele R, Terraciano L, et al. Selecting immunohistochemical cutoff scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol. 2007−60:1112−1116.